In this study, we investigated drug resistance levels in human immunodeficiency virus (HIV)-1-infected patients in Suzhou by retrospectively analyzing this property and the characteristics of circulating HIV-1 strains collected from 2009 to 2014. A total of 261 HIV-1-positive plasma samples, confirmed by the Suzhou CDC, were collected and evaluated to detect HIV-1 drug resistance genotypes using an in-house method. The pol gene fragment was amplified, and its nucleic acid sequence was determined by Sanger sequencing. Drug resistance mutations were then analyzed using the Stanford University HIV resistance database (https://hivdb.stanford.edu). A total of 216 pol gene fragments were amplified and sequenced with 16.7% (36/216) of sequences revealing these mutations. The drug resistance rates of protease, nucleoside reverse transcriptase, and non-nucleoside reverse transcriptase inhibitors (NNRTIs) were 4/36 (11.1%), 2/36 (5.6%), and 30/36 (83.3%), respectively. Five surveillance drug resistance mutations were found in 36 sequences, of which, three were found among specimens of men who have sex with men. Potential low-level resistance accounted for 33% of amino acid mutations associated with NNRTIs. Two of the mutations, M230L and L100I, which confer a high level of resistance efavirenz (EFV) and nevirapine (NVP) used as NNRTIs for first-line antiretroviral therapy (ART), were detected in this study. Therefore, when HIV-1 patients in Suzhou are administered fist-line ART, much attention should be paid to the status of these mutations that cause resistance to EVP, EFV, and NVP.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Yoshimura K (2017) Current status of HIV/AIDS in the ART era. J Infect Chemother 23:12–16
Group ISS, Lundgren JD, Babiker AG, Gordin F, Emery S, et al. (2015) Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 373: 795–807.
Lifson AR, Grund B, Gardner EM, Kaplan R, Denning E et al (2017) Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection. AIDS 31:953–963
Gunthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A et al (2014) Antiretroviral treatment of adult HIV infection: 2014 recommendations of the international antiviral society-USA panel. JAMA 312:410–425
Zhang F, Dou Z, Ma Y, Zhang Y, Zhao Y et al (2011) Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis 11:516–524
Sun J, Liu L, Shen J, Qi T, Wang Z et al (2015) Reasons and risk factors for the initial regimen modification in Chinese treatment-Naive patients with HIV Infection: a retrospective cohort analysis. PLoS ONE 10:e0133242
Hertogs K, Bloor S, Kemp SD, Van den Eynde C, Alcorn TM et al (2000) Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 14:1203–1210
Yuan Y, Tang S, Li Y, Yan D, Peng Q et al (2018) Characteristics of HIV-1 molecular epidemiology in Suzhou, China, from 2009 to 2014. Virol Sin 33:209–212
Zhang FJ, Pan J, Yu L, Wen Y, Zhao Y (2005) Current progress of China's free ART program. Cell Res 15:877–882
Lu G, Moriyama EN (2004) Vector NTI, a balanced all-in-one sequence analysis suite. Brief Bioinform 5:378–388
Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P et al (2007) HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 21:215–223
Clutter DS, Jordan MR, Bertagnolio S, Shafer RW (2016) HIV-1 drug resistance and resistance testing. Infect Genet Evol 46:292–307
Preston BD, Poiesz BJ, Loeb LA (1988) Fidelity of HIV-1 reverse transcriptase. Science 242:1168–1171
Coffin JM (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483–489
Moura ME, da Guarda Reis MN, Lima YA, Eulalio KD, Cardoso LP et al (2015) HIV-1 transmitted drug resistance and genetic diversity among patients from Piaui State, Northeast Brazil. J Med Virol 87:798–806
Rhee SY, Liu TF, Holmes SP, Shafer RW (2007) HIV-1 subtype B protease and reverse transcriptase amino acid covariation. PLoS Comput Biol 3:e87
Basson AE, Rhee SY, Parry CM, El-Khatib Z, Charalambous S et al (2015) Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 59:960–971
Xu HT, Quan Y, Schader SM, Oliveira M, Bar-Magen T et al (2010) The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity. Antimicrob Agents Chemother 54:2401–2408
Nomaguchi M, Miyake A, Doi N, Fujiwara S, Miyazaki Y, et al. (2014) Natural single-nucleotide polymorphisms in the 3' region of the HIV-1 pol gene modulate viral replication ability. J Virol 88: 4145–4160.
Giannini A, Vicenti I, Materazzi A, Boccuto A, Dragoni F et al (2019) The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro. J Antimicrob Chemother 74:607–613
WHO (2017) HIVDR Report; https://www.who.int/hiv/pub/ drugresistance/hivdr-report-2017 /en/
Zuo L, Liu K, Liu H, Hu Y, Zhang Z et al (2020) Trend of HIV-1 drug resistance in China: a systematic review and meta-analysis of data accumulated over 17 years (2001–2017). E Clin Med 18:100238
We gratefully acknowledge the contribution of the HIV-1 patients who participated in this study and also wish to thank the staff of the local CDC for recruiting participants, collecting samples, and technical assistance.
This work was supported by The National Natural Science Foundation of China (81802083, 31870867), State Key Laboratory of Veterinary Biotechnology Foundation (SKLVBF201916), Open Research Fund Program of the State Key Laboratory of Virology of China (2020IOV003), the Jiangsu Province Medical Innovation Team (CXTDB2017009), the Jiangsu Province's Key Discipline of Prenatal Diagnosis (FXK201746), and Jiangsu Provincial Key Research and Development Program (BE2019656).
Conflicts of interest
The authors declare that they have no conflicts of interest regarding this work.
This study has been approved by the Ethics Committee of the First Affiliated Hospital of Soochow University.
Informed consent was obtained from all individual participants included in the study.
The 216 pol sequences analyzed in the study have been submitted to GenBank with the accession number MN601502-601717.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Communicated by Wolfram H. Gerlich.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Song, Y., Hu, J., He, J. et al. Retrospective analysis of HIV-1 drug resistance mutations in Suzhou, China from 2009 to 2014. Virus Genes (2020). https://doi.org/10.1007/s11262-020-01774-0
- Drug resistance mutation
- Antiretroviral therapy